3 completed, 1 active not recruiting, 1 terminated. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Opsoclonus-Myoclonus Syndrome: new trials by email Literature Review of Opsoclonus-Myoclonus Syndrome trials Research Report on Opsoclonus-Myoclonus Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) Dexamethasone acetate, dexamethasone and cyclophosphamide, dexamethasone and rituximab - Opsoclonus Myoclonus Syndrome, Neuroblastoma | Phase 3 | Completed | Institut Curie | 102 | 2013-04-18 | 2025-02-03 |
| Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine - Autoimmune Disease, Neurologic Autoimmune Disease | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2008-06-01 | 2026-02-27 |
| Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome Opsoclonus-myoclonus Syndrome | Completed | National Pediatric Neuroinflammation Organization, Inc. | 400 | 2008-01-01 | 2017-05-23 | |
| Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma anti-CD20 (Rituximab) - Neuroblastoma, Opsoclonus-myoclonus | Phase 2 | Terminated | Jean M. Tersak, M.D. | 4 | 2005-07-01 | 2021-01-22 |
| Effectiveness of Rituximab in Pediatric OMS Patients. rituximab - Opsoclonus-myoclonus Syndrome, Opsoclonus | Phase 1 / Phase 2 | Completed | National Pediatric Neuroinflammation Organization, Inc. | 25 | 2005-06-01 | 2011-05-10 |
Neuroblastoma (3) · Ataxia (2) · Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (1) · Lambert-Eaton Myasthenic Syndrome (1) · Myasthenia Gravis (1) · Myoclonus (1) · Neuromyelitis Optica (1) · Ocular Motility Disorders (1) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1) · Rasmussen subacute encephalitis (1) · Stiff-Person Syndrome (1) · Vasculitis, Central Nervous System (1)
Central Nervous System Diseases (5) · Cranial Nerve Diseases (5) · Dyskinesias (5) · Eye Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Nervous System Diseases (5) · Nervous System Neoplasms (5) · Neurodegenerative Diseases (5) · Neurologic Manifestations (5) · Paraneoplastic Syndromes (5) · Paraneoplastic Syndromes, Nervous System (5) · Myoclonus (4) · Ocular Motility Disorders (4) · Neoplasms by Histologic Type (3)
Rituximab (3) · Antilymphocyte Serum (1) · Carmustine (1) · Cyclophosphamide (1) · Cytarabine (1) · Dexamethasone (1) · Etoposide (1) · Melphalan (1) · Peripheral Blood Stem Cell Transplantation (1) · Prednisone (1) · carmustine, poliferprosan 20 drug combination (1) · deltacortene (1) · dexamethasone acetate (1) · prednylidene (1) · thymoglobulin (1)
National Pediatric Neuroinflammation Organization, Inc. (2) · Fred Hutchinson Cancer Center (1) · Institut Curie (1) · Jean M. Tersak, M.D. (1)
United States (3) · Austria (1) · France (1) · Italy (1) · Spain (1) · Sweden (1) · Switzerland (1) · United Kingdom (1)
Elizabeth D Tate, FNP, MN (1) · Gudrun Schleiermacher, MD (1) · Jean M Tersak, M.D. (1) · Leona Holmberg (1) · Michael R Pranzatelli, M.D. (1) · Michael R Pranzatelli, MD (1)
PMID 21211990, PMID 19838774, PMID 20606544, PMID 22264765, PMID 23324534, PMID 23340773, PMID 23380454, PMID 23600831, PMID 23659672, PMID 23764550, PMID 24342231